Kuros Biosciences

𝗙𝗼𝗹𝗹𝗼𝘄𝗶𝗻𝗴 𝗙𝗗𝗔 𝗰𝗹𝗲𝗮𝗿𝗮𝗻𝗰𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗠𝗮𝗴𝗻𝗲𝘁𝗢𝘀™ 𝗠𝗜𝗦 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆 𝗦𝘆𝘀𝘁𝗲𝗺, 𝗗𝗿. Daniel Park (𝗦𝗼𝘂𝘁𝗵𝗳𝗶𝗲𝗹𝗱, 𝗠𝗜) 𝘄𝗮𝘀 𝗮𝗺𝗼𝗻𝗴 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝗨.𝗦. 𝘀𝘂𝗿𝗴𝗲𝗼𝗻𝘀 𝘁𝗼 𝗽𝘂𝘁 𝗶𝘁 𝗶𝗻𝘁𝗼 𝗽𝗿𝗮𝗰𝘁𝗶𝗰𝗲. “MagnetOs MIS delivered smooth, precise graft placement in a typically challenging MIS TLIF case – no preparation, no thawing, just immediate efficiency. With streamlined handling and compelling clinical data, it represents a meaningful advancement for surgeons who value both efficiency and biologically robust healing,” said Dr. Park. Thank you, Dr. Park, for sharing your early experience. We look forward to seeing more cases as adoption of the system expands, with full commercial launch anticipated this fall. #KurosBiosciences #MagnetOs #GrowBoneMagnetOs #MIS #NeedleGrip

"𝗜𝗖𝗬𝗠𝗜" — 𝗜𝗻 𝗰𝗮𝘀𝗲 𝘆𝗼𝘂 𝗺𝗶𝘀𝘀𝗲𝗱 𝗶𝘁, 𝘁𝗵𝗲 𝗿𝗲𝗰𝗼𝗿𝗱𝗶𝗻𝗴 𝗼𝗳 𝘁𝗵𝗲 𝗞𝘂𝗿𝗼𝘀 𝗕𝗶𝗼𝘀𝗰𝗶𝗲𝗻𝗰𝗲𝘀’ 𝟮𝟬𝟮𝟱 𝗛𝗮𝗹𝗳 𝗬𝗲𝗮𝗿 𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗥𝗲𝘀𝘂𝗹𝘁𝘀 𝘄𝗲𝗯𝗰𝗮𝘀𝘁 𝗶𝘀 𝗻𝗼𝘄 𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲! The webcast, presented by Chris Fair, CEO, and Daniel Geiger, CFO, highlighted Kuros' strong commercial and operational performance, innovation, and pipeline progress. Both leaders shared insights on strategic priorities and addressed key questions from investors. 𝗧𝗲𝗻 𝗛𝟭 𝟮𝟬𝟮𝟱 𝗳𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗮𝗻𝗱 𝗼𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝘁𝗼 𝗸𝗻𝗼𝘄: #1 - Total Medical Device sales rose by 𝟳𝟴% to USD 63.5 million in H1 2025 #2 - Total Group achieved its 𝗳𝗶𝗿𝘀𝘁-𝗲𝘃𝗲𝗿 𝗼𝗽𝗲𝗿𝗮𝘁𝗶𝗻𝗴 𝗽𝗿𝗼𝗳𝗶𝘁, reaching USD 3.5 million #3 - Total Group 𝗮𝗱𝗷𝘂𝘀𝘁𝗲𝗱 𝗘𝗕𝗜𝗧𝗗𝗔 𝗿𝗲𝗮𝗰𝗵𝗲𝗱 𝗨𝗦𝗗 𝟳.𝟴 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 #4 - The Group continues to expect 𝘀𝗮𝗹𝗲𝘀 𝗴𝗿𝗼𝘄𝘁𝗵 𝗼𝗳 𝗮𝘁 𝗹𝗲𝗮𝘀𝘁 𝟲𝟬% in 2025 #5 - Medtronic U.S. Spine partnership continues to gain traction #6 - FDA clearance & first cases with MagnetOsᵀᴹ MIS Delivery System #7 - Continued momentum in extremities market #8 - Global expansion accelerated with MagnetOs Putty approval in Brazil #9 - First Capital Markets Day successfully completed #10 - New U.S. headquarters & production facility construction underway Watch the full presentation here: https://hubs.ly/Q03DfVm90 #KurosBiosciences #H12025 #GrowBoneMagnetOs #FinancialResults #MagnetOs #Growth

𝗞𝘂𝗿𝗼𝘀 𝗕𝗶𝗼𝘀𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘀 𝗥𝗲𝗰𝗼𝗿𝗱 𝗛𝟭 𝗥𝗲𝘀𝘂𝗹𝘁𝘀 𝗮𝗻𝗱 𝗙𝗶𝗿𝘀𝘁-𝗘𝘃𝗲𝗿 𝗢𝗽𝗲𝗿𝗮𝘁𝗶𝗻𝗴 𝗣𝗿𝗼𝗳𝗶𝘁 Kuros Biosciences is pleased to announce record-breaking results for the first half of 2025, marking a pivotal milestone in our growth journey. 𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: • 78% growth in total medical device sales to USD 63.5M (H1 2024: USD 35.7M) • 77% growth in direct MagnetOs™ sales to USD 62.7M (H1 2024: USD 35.4M) • First-ever operating profit of USD 3.5M (H1 2024: operating loss of USD (0.2M)) • Strong cash position of USD 18.4M as of June 30, 2025 • Reporting currency changed to USD to align with our primary market in the U.S. • The Group continues to expect sales growth of at least 60% in 2025 𝗢𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗺𝗼𝗺𝗲𝗻𝘁𝘂𝗺 𝗶𝗻𝗰𝗹𝘂𝗱𝗲𝘀: • Acceleration of our Medtronic U.S. spine partnership, expanding U.S. access • FDA clearance and first cases with the MagnetOs MIS Delivery System • Continued progress in the extremities market through targeted engagement with a dedicated team’s omnichannel strategy • Global expansion with ANVISA approval of MagnetOs Granules and MagnetOs Putty in Brazil and additional international clearances • First Capital Markets Day successfully completed with over 130 attendees • Groundbreaking for our new Atlanta headquarters and manufacturing facility to support scaling and surgeon education CEO Chris Fair commented: “We recorded exceptional company revenue growth of 78%, marking a pivotal phase of scale and impact for Kuros. An outstanding accomplishment is that the group has for the first time ever recorded an operating profit. With FDA clearance and U.S. launch of MagnetOs MIS, accelerating growth in extremities, and entry into new international markets, we continue to deliver with innovation, precision, and purpose. The strategic alliance with Medtronic is expanding our reach across U.S. spine markets, while our new Atlanta headquarters will enable domestic production and an immersive educational experience for surgeons, partners, and investors. Backed by strong financial performance, an experienced and diverse board, and momentum across all segments, we are well-positioned to sustain growth and create long-term value for patients, providers, and shareholders globally.” Read the full release here: https://hubs.ly/Q03CLk4z0 #KurosBiosciences #GrowBoneMagnetOs #MagnetOs #H12025Results #MedicalDevices #Orthopedics #BoneHealing #FinancialResults #Growth #GlobalExpansion

𝗔𝗻𝗼𝘁𝗵𝗲𝗿 𝗲𝗾𝘂𝗶𝘁𝘆 𝗮𝗻𝗮𝗹𝘆𝘀𝘁 𝗰𝗼𝗻𝗳𝗶𝗿𝗺𝘀 𝗞𝘂𝗿𝗼𝘀 𝗰𝗼𝘃𝗲𝗿𝗮𝗴𝗲! As of August 5th, we are now covered by a third equity analyst, Baader, who has initiated coverage with a 𝗯𝘂𝘆 rating. Investor confidence closely matches surgeon confidence when it comes to MagnetOsᵀᴹ' ability to grow bone, and grow market adoption. We're excited to share this growing recognition of our momentum and sustainable growth opportunity. As Baader put it: Solid fuse, strong case To read the full analyst report, click here: https://hubs.ly/Q03C8xJf0 #KurosBiosciences #InvestorRelations #MagnetOs

Spinal biologics: What’s real, what’s not, and what actually matters. Catch the full recording of Spinal Biologics Demystified—Separating Fact from Fiction, a Broadwater webinar supported by Kuros Biosciences. Led by moderator Dr. Alpesh A Patel MD MBA FACS and featuring Drs. Andrew A. Sama MD and Faheem Sandhu, this expert panel cuts through the noise to examine: ➤ The fundamentals of bone healing and osteoimmunology ➤ Evidence-based comparisons of spinal biologics ➤ Real-world clinical outcomes and safety ➤ Case examples and cost-justification strategies Catch the replay: https://hubs.ly/Q03zYf_y0 #KurosBiosciences #MagnetOs #SpineSurgery #Orthobiologics #Level1Data #GrowBoneMagnetOs #NeedleGrip

🎉 Thrilled to see MagnetOs MIS officially launched — and already making its way into the OR! I’ve had the privilege of managing this project from development through design transfer, and I’m so proud to see it reach this milestone. 🙏 Grateful to be part of a team at Kuros Biosciences that consistently goes the extra mile to bring meaningful innovation to surgeons and patients. A huge thank you to all my amazing colleagues — your dedication, creativity, and collaboration made this possible. Here’s to continued growth and impact! #MedTech #Innovation #SpineSurgery #ProductLaunch #MagnetOsMIS #Bonegraft #NeedleGrip #KurosBiosciences

𝐊𝐮𝐫𝐨𝐬 𝐁𝐢𝐨𝐬𝐜𝐢𝐞𝐧𝐜𝐞𝐬 𝐥𝐚𝐮𝐧𝐜𝐡𝐞𝐬 𝐌𝐚𝐠𝐧𝐞𝐭𝐎𝐬ᵀᴹ 𝐌𝐈𝐒 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐒𝐲𝐬𝐭𝐞𝐦 𝐛𝐲 𝐜𝐨𝐦𝐩𝐥𝐞𝐭𝐢𝐧𝐠 𝐟𝐢𝐫𝐬𝐭 𝐜𝐚𝐬𝐞𝐬, 𝐚𝐧𝐝 𝐜𝐨𝐧𝐭𝐢𝐧𝐮𝐞𝐬 𝐠𝐥𝐨𝐛𝐚𝐥 𝐞𝐱𝐩𝐚𝐧𝐬𝐢𝐨𝐧 𝐰𝐢𝐭𝐡 𝐢𝐧𝐜𝐫𝐞𝐦𝐞𝐧𝐭𝐚𝐥 𝐁𝐫𝐚𝐳𝐢𝐥 𝐜𝐥𝐞𝐚𝐫𝐚𝐧𝐜𝐞. 𝖪𝗎𝗋𝗈𝗌 𝖡𝗂𝗈𝗌𝖼𝗂𝖾𝗇𝖼𝖾𝗌 𝗂𝗌 𝗉𝗅𝖾𝖺𝗌𝖾𝖽 𝗍𝗈 𝖺𝗇𝗇𝗈𝗎𝗇𝖼𝖾 𝗍𝗐𝗈 𝗆𝗂𝗅𝖾𝗌𝗍𝗈𝗇𝖾𝗌 𝗍𝗁𝖺𝗍 𝖾𝗑𝗉𝖺𝗇𝖽 𝗀𝗅𝗈𝖻𝖺𝗅 𝖺𝖼𝖼𝖾𝗌𝗌 𝖺𝗇𝖽 𝗎𝗍𝗂𝗅𝗂𝗓𝖺𝗍𝗂𝗈𝗇 𝗈𝖿 𝗈𝗎𝗋 𝖺𝖽𝗏𝖺𝗇𝖼𝖾𝖽 𝖻𝗈𝗇𝖾 𝗀𝗋𝖺𝖿𝗍 𝗍𝖾𝖼𝗁𝗇𝗈𝗅𝗈𝗀𝗒: • 𝖥𝗂𝗋𝗌𝗍 𝖴.𝖲. 𝖼𝖺𝗌𝖾𝗌 𝗈𝖿 𝗍𝗁𝖾 𝖬𝖺𝗀𝗇𝖾𝗍𝖮𝗌 𝖬𝖨𝖲 𝖣𝖾𝗅𝗂𝗏𝖾𝗋𝗒 𝖲𝗒𝗌𝗍𝖾𝗆, 𝖿𝗈𝗅𝗅𝗈𝗐𝗂𝗇𝗀 𝖥𝖣𝖠 𝖼𝗅𝖾𝖺𝗋𝖺𝗇𝖼𝖾 𝗂𝗇 𝖬𝖺𝗒 • 𝖠𝖭𝖵𝖨𝖲𝖠 𝖺𝗉𝗉𝗋𝗈𝗏𝖺𝗅 𝗈𝖿 𝖬𝖺𝗀𝗇𝖾𝗍𝖮𝗌 𝖯𝗎𝗍𝗍𝗒 𝗂𝗇 𝖡𝗋𝖺𝗓𝗂𝗅, 𝖿𝗈𝗅𝗅𝗈𝗐𝗂𝗇𝗀 𝗋𝖾𝖼𝖾𝗇𝗍 𝖬𝖺𝗀𝗇𝖾𝗍𝖮𝗌 𝖦𝗋𝖺𝗇𝗎𝗅𝖾𝗌 𝖺𝗉𝗉𝗋𝗈𝗏𝖺𝗅 𝖳𝗁𝖾 𝖥𝖣𝖠 𝖼𝗅𝖾𝖺𝗋𝖺𝗇𝖼𝖾 𝖾𝗇𝖺𝖻𝗅𝖾𝗌 𝗌𝗍𝗋𝖾𝖺𝗆𝗅𝗂𝗇𝖾𝖽 𝖽𝖾𝗅𝗂𝗏𝖾𝗋𝗒 𝗈𝖿 𝖬𝖺𝗀𝗇𝖾𝗍𝖮𝗌 𝗂𝗇 𝗆𝗂𝗇𝗂𝗆𝖺𝗅𝗅𝗒 𝗂𝗇𝗏𝖺𝗌𝗂𝗏𝖾 𝗌𝗉𝗂𝗇𝖾 𝗉𝗋𝗈𝖼𝖾𝖽𝗎𝗋𝖾𝗌. 𝖮𝗇𝖾 𝗈𝖿 𝗍𝗁𝖾 𝖿𝗂𝗋𝗌𝗍 𝖴.𝖲. 𝖼𝖺𝗌𝖾𝗌 𝗎𝗌𝗂𝗇𝗀 𝗍𝗁𝖾 𝗌𝗒𝗌𝗍𝖾𝗆 𝗐𝖺𝗌 𝖼𝗈𝗆𝗉𝗅𝖾𝗍𝖾𝖽 𝖻𝗒 𝖣𝗋. 𝖣𝖺𝗇𝗂𝖾𝗅 𝖯𝖺𝗋𝗄, 𝗈𝗋𝗍𝗁𝗈𝗉𝖾𝖽𝗂𝖼 𝗌𝗉𝗂𝗇𝖾 𝗌𝗎𝗋𝗀𝖾𝗈𝗇, 𝗂𝗇 𝖲𝗈𝗎𝗍𝗁𝖿𝗂𝖾𝗅𝖽, 𝖬𝗂𝖼𝗁𝗂𝗀𝖺𝗇. 𝖪𝗎𝗋𝗈𝗌 𝖺𝗇𝗍𝗂𝖼𝗂𝗉𝖺𝗍𝖾𝗌 𝖾𝗑𝗉𝖺𝗇𝖽𝗂𝗇𝗀 𝖺𝗏𝖺𝗂𝗅𝖺𝖻𝗂𝗅𝗂𝗍𝗒 𝗈𝖿 𝗍𝗁𝖾 𝖬𝖨𝖲 𝗌𝗒𝗌𝗍𝖾𝗆 𝗐𝗂𝗍𝗁 𝖺 𝖿𝗎𝗅𝗅 𝖼𝗈𝗆𝗆𝖾𝗋𝖼𝗂𝖺𝗅 𝗅𝖺𝗎𝗇𝖼𝗁 𝗍𝗁𝗂𝗌 𝖿𝖺𝗅𝗅. “𝖬𝖺𝗀𝗇𝖾𝗍𝖮𝗌 𝖬𝖨𝖲 𝖽𝖾𝗅𝗂𝗏𝖾𝗋𝖾𝖽 𝗌𝗆𝗈𝗈𝗍𝗁, 𝗉𝗋𝖾𝖼𝗂𝗌𝖾 𝗀𝗋𝖺𝖿𝗍 𝗉𝗅𝖺𝖼𝖾𝗆𝖾𝗇𝗍 𝗂𝗇 𝖺 𝗍𝗒𝗉𝗂𝖼𝖺𝗅𝗅𝗒 𝖼𝗁𝖺𝗅𝗅𝖾𝗇𝗀𝗂𝗇𝗀 𝖬𝖨𝖲 𝖳𝖫𝖨𝖥 𝖼𝖺𝗌𝖾 – 𝗇𝗈 𝗉𝗋𝖾𝗉𝖺𝗋𝖺𝗍𝗂𝗈𝗇, 𝗇𝗈 𝗍𝗁𝖺𝗐𝗂𝗇𝗀, 𝗃𝗎𝗌𝗍 𝗂𝗆𝗆𝖾𝖽𝗂𝖺𝗍𝖾 𝖽𝖾𝗅𝗂𝗏𝖾𝗋𝗒 𝖺𝗇𝖽 𝖾𝖿𝖿𝗂𝖼𝗂𝖾𝗇𝖼𝗒. 𝖨𝗍 𝗉𝖺𝗂𝗋𝗌 𝗌𝗍𝗋𝖾𝖺𝗆𝗅𝗂𝗇𝖾𝖽 𝗁𝖺𝗇𝖽𝗅𝗂𝗇𝗀 𝗐𝗂𝗍𝗁 𝖼𝗈𝗆𝗉𝖾𝗅𝗅𝗂𝗇𝗀 𝖼𝗅𝗂𝗇𝗂𝖼𝖺𝗅 𝖽𝖺𝗍𝖺, 𝗆𝖺𝗄𝗂𝗇𝗀 𝗂𝗍 𝖺 𝗆𝖾𝖺𝗇𝗂𝗇𝗀𝖿𝗎𝗅 𝖺𝖽𝗏𝖺𝗇𝖼𝖾𝗆𝖾𝗇𝗍 𝖿𝗈𝗋 𝗌𝗎𝗋𝗀𝖾𝗈𝗇𝗌 𝗐𝗁𝗈 𝗏𝖺𝗅𝗎𝖾 𝖻𝗈𝗍𝗁 𝖾𝖿𝖿𝗂𝖼𝗂𝖾𝗇𝖼𝗒 𝖺𝗇𝖽 𝖻𝗂𝗈𝗅𝗈𝗀𝗂𝖼𝖺𝗅𝗅𝗒 𝗋𝗈𝖻𝗎𝗌𝗍 𝗁𝖾𝖺𝗅𝗂𝗇𝗀,” 𝗌𝖺𝗂𝖽 𝖣𝗋. 𝖯𝖺𝗋𝗄. 𝖠𝗍 𝗍𝗁𝖾 𝗌𝖺𝗆𝖾 𝗍𝗂𝗆𝖾, 𝗍𝗁𝖾 𝖺𝗉𝗉𝗋𝗈𝗏𝖺𝗅 𝗈𝖿 𝖬𝖺𝗀𝗇𝖾𝗍𝖮𝗌 𝖯𝗎𝗍𝗍𝗒 𝗂𝗇 𝖡𝗋𝖺𝗓𝗂𝗅 𝖼𝗈𝗆𝗉𝗅𝖾𝗆𝖾𝗇𝗍𝗌 𝗈𝗎𝗋 𝖾𝗑𝗂𝗌𝗍𝗂𝗇𝗀 𝗋𝖾𝗀𝗂𝗌𝗍𝗋𝖺𝗍𝗂𝗈𝗇 𝖿𝗈𝗋 𝖬𝖺𝗀𝗇𝖾𝗍𝖮𝗌 𝖦𝗋𝖺𝗇𝗎𝗅𝖾𝗌, 𝖿𝗎𝗋𝗍𝗁𝖾𝗋 𝗌𝗍𝗋𝖾𝗇𝗀𝗍𝗁𝖾𝗇𝗂𝗇𝗀 𝗈𝗎𝗋 𝗉𝗋𝖾𝗌𝖾𝗇𝖼𝖾 𝗂𝗇 𝗍𝗁𝖾 𝖲𝗈𝗎𝗍𝗁 𝖠𝗆𝖾𝗋𝗂𝖼𝖺𝗇 𝗌𝗉𝗂𝗇𝖾 𝖺𝗇𝖽 𝗈𝗋𝗍𝗁𝗈𝗉𝖾𝖽𝗂𝖼𝗌 𝗆𝖺𝗋𝗄𝖾𝗍. 𝖱𝖾𝖺𝖽 𝗍𝗁𝖾 𝖿𝗎𝗅𝗅 𝗉𝗋𝖾𝗌𝗌 𝗋𝖾𝗅𝖾𝖺𝗌𝖾 𝗁𝖾𝗋𝖾: https://hubs.ly/Q03Bk66X0 #𝖪𝗎𝗋𝗈𝗌𝖡𝗂𝗈𝗌𝖼𝗂𝖾𝗇𝖼𝖾𝗌 #𝖬𝖺𝗀𝗇𝖾𝗍𝖮𝗌 #𝖬𝖨𝖲 #𝖥𝖣𝖠𝖼𝗅𝖾𝖺𝗋𝖺𝗇𝖼𝖾 #𝖡𝗋𝖺𝗓𝗂𝗅𝖠𝗉𝗉𝗋𝗈𝗏𝖺𝗅 #𝖮𝗋𝗍𝗁𝗈𝗉𝖾𝖽𝗂𝖼𝗌 #𝖦𝗋𝗈𝗐𝖡𝗈𝗇𝖾𝖬𝖺𝗀𝗇𝖾𝗍𝖮𝗌 #𝖦𝗅𝗈𝖻𝖺𝗅𝖤𝗑𝗉𝖺𝗇𝗌𝗂𝗈𝗇

What evidence exists for using demineralized bone matrices (DBM) in foot and ankle surgeries? A recent review evaluated the clinical and radiographic outcomes with DBM used as an extender in foot and ankle surgical procedures. The study identified 12 studies and 363 patients who fit the inclusion criteria. The authors concluded that DBM led to satisfactory osseous union rates but cite a lack of quality evidence and overall low level of evidence available for use of DBMs. To read the full article, click here: https://hubs.ly/Q03z7B2C0 Unlike DBMs, MagnetOsᵀᴹ forms bone by polarizing the patient’s immune cells for predictable bone formation. MagnetOs has high quality Level 1 evidence when used standalone, without mixing with autologous bone, in the spine.¹ Foot and ankle studies also reveal the power of MagnetOs to form bone for these indications.²,³ Be sure to follow our Kuros Biosciences Extremities page for more related content: https://hubs.ly/Q03z7BHM0 1. Stempels, et al. 𝑆𝑝𝑖𝑛𝑒. 2024;49(19):1323-1331. 2. Fusco et al. 𝐽𝑢𝑛𝑖𝑝𝑒𝑟. 2022. 3. Fusco et al. 𝐹𝑜𝑜𝑡 & 𝐴𝑛𝑘𝑙𝑒 𝑆𝑢𝑟𝑔𝑒𝑟𝑦. 2022.

What is the fusion rate in lumbar interbody fusion surgeries when using MagnetOsᵀᴹ? A recent publication by Wakelin et al evaluated MagnetOs performance in lumbar interbody fusion surgeries. The retrospective analysis revealed a 𝟗𝟓.𝟕𝟎% 𝐟𝐮𝐬𝐢𝐨𝐧 𝐫𝐚𝐭𝐞. There was no difference in performance when MagnetOs was used standalone or mixed with autograft. Click here to read the full article: https://hubs.ly/Q03yw14c0 To learn more about evidence for the effectiveness of MagnetOs to promote fusion in interbody surgeries, schedule a Meet the Expert: https://hubs.ly/Q03yw3SN0

Did you know how the immune system plays a key role in bone healing? Macrophages are one of the immune system’s first responders, adapting their role based on their microenvironment. M1 macrophages are pro-inflammatory and stimulate fibroblast proliferation, often leading to scar tissue formation.¹ With MagnetOsᵀᴹ, the immune response shifts, M2 macrophages take the lead, promoting healing and activating stem cells to regenerate bone.¹,² References: 1. Italiani, et al. Front Immunol. 2014;5:514 2. Loi, et al. Stem Cell Res Ther. 2016;7:15